Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.

@article{Djingarey2012EffectivelyIA,
  title={Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.},
  author={Mamoudou Harouna Djingarey and Rodrigue Barry and Mete Bonkoungou and Sylvestre R.M. Tiendrebeogo and Rene Sebgo and Denis Kandolo and Cl{\'e}ment Lingani and Marie-Pierre Pr{\'e}ziosi and Patrick L. F. Zuber and William A. Perea and St{\'e}phane Hugonnet and Nora Dellepiane de Rey Tolve and Carole Tevi-Benissan and Thomas A. Clark and Leonard W. Mayer and Ryan Novak and Nancy E Messonier and Monique Berlier and Desire Toboe and Deo Nshimirimana and Richard Mihigo and Teresa Aguado and Fabien V.K. Diomand{\'e} and Paul A. Kristiansen and Dominique A Caugant and F Marc Laforce},
  journal={Vaccine},
  year={2012},
  volume={30 Suppl 2},
  pages={B40-5}
}
A new Group A meningococcal (Men A) conjugate vaccine, MenAfriVac™, was prequalified by the World Health Organization (WHO) in June 2010. Because Burkina Faso has repeatedly suffered meningitis epidemics due to Group A Neisseria meningitidis special efforts were made to conduct a country-wide campaign with the new vaccine in late 2010 and before the onset of the next epidemic meningococcal disease season beginning in January 2011. In the ensuing five months (July-November 2010) the following… CONTINUE READING